Applied Therapeutics, Inc.

Equities

APLT

US03828A1016

Biotechnology & Medical Research

Market Closed - Nasdaq 04:00:00 2024-04-19 pm EDT 5-day change 1st Jan Change
4.38 USD -7.59% Intraday chart for Applied Therapeutics, Inc. -15.12% +30.75%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Applied Therapeutics, Inc. Announces Management Changes CI
Applied Therapeutics Shares Slip 13% After FDA Extends Drug Review DJ
FDA Extends Review Period for Applied Therapeutics Genetic Disease Treatment DJ
Applied Therapeutics Gets NDA Review Period Extension for Galactosemia Treatment -- Shares Fall After Hours MT
US FDA extends review of Applied Therapeutics' genetic disease drug RE
Applied Therapeutics, Inc. Provides FDA Update on PDUFA Target Action Date for Govorestat for the Treatment of Classic Galactosemia CI
RBC Initiates Applied Therapeutics at Outperform, Speculative Risk With $12 Price Target, Sees Lead Drug Govorestat 'Well-Positioned for Success' MT
UBS Adjusts Applied Therapeutics Price Target to $13 From $12, Maintains Buy Rating MT
UBS Adjusts Applied Therapeutics Price Target to $12 From $4, Maintains Buy Rating MT
Applied Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Earnings Flash (APLT) APPLIED THERAPEUTICS Reports Q4 Revenue $10M MT
Applied Therapeutics, Inc. announced that it has received $99.997998 million in funding from a group of investors CI
Applied Therapeutics' NDA for Govorestat Accepted by FDA; Launches $100 Million Private Placement; Shares Jump MT
Applied Therapeutics Shares Surge on FDA Review, $100 Million Funding Round DJ
Leerink Partners Initiates Applied Therapeutics at Outperform Rating $12 Price Target MT
Sector Update: Health Care Stocks Higher Late Afternoon MT
Sector Update: Health Care MT
Applied Therapeutics Says Phase 3 Trial of Govorestat Meets Interim Primary Goal; Shares Rise MT
Transcript : Applied Therapeutics, Inc. - Special Call
Applied Therapeutics, Inc. Announces Positive Interim 12-Month Results from the Ongoing Phase 3 Inspire Trial CI
Applied Therapeutics, Inc. Announces Positive Results from 12-Month Interim Analysis of Govorestat (At-007) in the Ongoing Inspire Phase 3 Trial in Sorbitol Dehydrogenase Deficiency CI
Wall Street ends topsy-turvy day marginally up RE
Top MIdday Decliners MT
S&P 500, Nasdaq climb as fresh data boosts rate-cut bets again RE
Global markets live: Walt Disney, Qiagen, Mobileye, Apple, CVS Health... Our Logo
Chart Applied Therapeutics, Inc.
More charts
Applied Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It is focused on developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need. The Company’s lead drug candidate, govorestat, is a novel central nervous system penetrant Aldose Reductase Inhibitor (ARI) for the treatment of central nervous system (CNS) rare metabolic diseases, including Galactosemia, Sorbitol Dehydrogenase (SORD) Deficiency, and PMM2-CDG. The Company is also developing AT-001, a novel potent ARI, for the treatment of Diabetic Cardiomyopathy (DbCM) a fatal fibrosis of the heart. It has completed a Phase I/II clinical trial evaluating AT-001 in approximately 120 patients with type 2 diabetes, in which no drug-related adverse effects or tolerability issues were observed. The preclinical pipeline also includes AT-003, an ARI designed to cross through the back of the eye when dosed orally, for the treatment of Diabetic retinopathy.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
4.38 USD
Average target price
11.6 USD
Spread / Average Target
+164.84%
Consensus
  1. Stock Market
  2. Equities
  3. APLT Stock
  4. News Applied Therapeutics, Inc.
  5. Sector Update: Health Care Stocks Higher Late Afternoon